Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR201
- Development stage
- Phase 2
- Lead developer
- Virax Holdings
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
VIR201 is an experimental DNA vaccine that utilizes Co-X-Gene technology, in which HIV and human genetic material are grafted onto a harmless fowlpox virus. The approach is designed to stimulate an immune response against HIV by introducing genetic material encoding HIV antigens into the body via a viral vector. This vaccine candidate represents a gene-based immunization strategy for the prevention or treatment of HIV infection[1].
- Other names
- rFPV expressing HIV gag-pol antigensfowlpox virus expressing HIV gag-pol antigens
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)HIV-1 antigens
Beyond the preview
Go deeper on VIR201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR201.